-
EP2627635
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP2627635
| EP2627635 - SALTS OF ARYLSULFONAMIDE CCR3 ANTAGONISTS [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 29.07.2016 Database last updated on 03.09.2024 | Most recent event Tooltip | 29.07.2016 | Application deemed to be withdrawn | published on 31.08.2016 [2016/35] | Applicant(s) | For all designated states Axikin Pharmaceuticals, Inc. 6185 E. Cornerstone Court 106 San Diego, CA 92121 / US | [2016/33] |
| Former [2014/29] | For all designated states Axikin Pharmaceuticals, Inc. 4940 Carroll Canyon Road, Suite 100 San Diego, CA 92121 / US | ||
| Former [2013/34] | For all designated states Axikin Pharmaceuticals, Inc. 10835 Road to the Cure, Suite 250 San Diego, CA 92121 / US | Inventor(s) | 01 /
LY, Tai, Wei 10824 Caminito Colorado San Diego CA 92131 / US | [2013/34] | Representative(s) | Savic, Bojan, et al Jones Day Rechtsanwälte Attorneys-at-Law Patentanwälte Prinzregentenstrasse 11 80538 München / DE | [2013/52] |
| Former [2013/34] | Ritter, Thomas Kurt Jones Day Prinzregentenstrasse 11 80538 München / DE | Application number, filing date | 11776943.0 | 10.10.2011 | WO2011US55550 | Priority number, date | US20100391926P | 11.10.2010 Original published format: US 391926 P | [2013/34] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2012051090 | Date: | 19.04.2012 | Language: | EN | [2012/16] | Type: | A1 Application with search report | No.: | EP2627635 | Date: | 21.08.2013 | Language: | EN | The application published by WIPO in one of the EPO official languages on 19.04.2012 takes the place of the publication of the European patent application. | [2013/34] | Search report(s) | International search report - published on: | EP | 19.04.2012 | Classification | IPC: | C07D211/54, C07D241/04, A61K31/495, A61P37/00 | [2013/34] | CPC: |
C07D295/26 (EP,US);
A61P1/00 (EP);
A61P1/04 (EP);
A61P11/00 (EP);
A61P11/02 (EP);
A61P11/06 (EP);
A61P17/00 (EP);
A61P17/02 (EP);
A61P17/06 (EP);
A61P17/10 (EP);
A61P19/02 (EP);
A61P25/00 (EP);
A61P27/14 (EP);
A61P29/00 (EP);
A61P35/02 (EP);
A61P37/00 (EP);
A61P37/02 (EP);
A61P37/06 (EP);
A61P37/08 (EP);
A61P43/00 (EP);
A61P7/00 (EP);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2013/34] | Title | German: | SALZE AUS ARYLSULFONAMID-CCR3-ANTAGONISTEN | [2013/34] | English: | SALTS OF ARYLSULFONAMIDE CCR3 ANTAGONISTS | [2013/34] | French: | SELS D'ANTAGONISTES ARYLSULFONAMIDE DE CCR3 | [2013/34] | Entry into regional phase | 13.05.2013 | National basic fee paid | 13.05.2013 | Designation fee(s) paid | 13.05.2013 | Examination fee paid | Examination procedure | deleted | Communication of intention to grant the patent | 13.05.2013 | Examination requested [2013/34] | 17.12.2013 | Amendment by applicant (claims and/or description) | 15.12.2014 | Despatch of a communication from the examining division (Time limit: M06) | 24.06.2015 | Reply to a communication from the examining division | 29.10.2015 | Despatch of a communication from the examining division (Time limit: M04) | 10.03.2016 | Application deemed to be withdrawn, date of legal effect [2016/35] | 05.04.2016 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2016/35] | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 15.12.2014 | Fees paid | Renewal fee | 14.10.2013 | Renewal fee patent year 03 | 14.10.2014 | Renewal fee patent year 04 | 12.10.2015 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [X]US2003144277 (DELUCCA GEORGE V [US]) [X] 1-64 * page 1, line 5 - page 1, line 10; example - *; | [X]WO2004084898 (BAYER HEALTHCARE AG [DE], et al) [X] 1-64 * page 1, line 3 - page 1, line 8; example - *; | [X]EP1849469 (ACTIMIS PHARMACEUTICALS INC [US]) [X] 1-64 * page 1, line 5 - page 1, line 9; example - *; | [X]US2009286771 (LI YINGFU [US], et al) [X] 1-64* page 1, paragraph [0001];;; example - *; | [XP]WO2010123960 (AXIKIN PHARMACEUTICALS INC [US], et al) [XP] 1-64 * page 1, paragraph [0001];;; example - *; | [XP]WO2010123959 (AXIKIN PHARMACEUTICALS INC [US], et al) [XP] 1-64 * page 1, paragraph [0001];; example - * | by applicant | US3536809 | US3598123 | US3845770 | US3916899 | US4008719 | US4328245 | US4409239 | US4410545 | US5033252 | US5052558 | US5059595 | US5073543 | US5120548 | US5323907 | US5354556 | US5591767 | US5612059 | US5639476 | US5639480 | US5674533 | US5698220 | US5709874 | US5733566 | US5739108 | US5759542 | US5798119 | US5840674 | US5891474 | US5900252 | US5922356 | US5972891 | US5972366 | US5980945 | US5985307 | US5993855 | US6004534 | US6039975 | US6045830 | US6048736 | US6060082 | US6071495 | US6087324 | US6113943 | US6120751 | US6131570 | US6139865 | US6197350 | US6248363 | US6253872 | US6264970 | US6267981 | US6271359 | US6274552 | US6316652 | US6350458 | WO0217918 | US6376461 | US6419961 | US6589548 | US6613358 | US6699500 | US2005070582 | US2007155725 | - COMBADIERE ET AL., J. BIOL. CHEM., (1995), vol. 270, pages 16491 - 16494 | - POST ET AL., J. IMMUNOL., (1995), vol. 155, pages 5299 - 5305 | - DURHAM, KAY, CLIN. ALLERGY, (1985), vol. 15, pages 411 - 418 | - KROEGEL ET AL., J. ALLERGY CLIN. IMMUNOL., (1994), vol. 93, pages 725 - 734 | - DURHAM, CLIN. EXP. ALLERGY, (1998), vol. 28, no. 2, pages 11 - 16 | - LEUNG, J. ALLERGY CLIN. IMMUNOL., (1999), vol. 104, pages 99 - 108 | - BISCHOFF ET AL., AM. J. GASTRO., (1999), vol. 94, pages 3521 - 3529 | - EVANS ET AL., J. CLIN. INVEST., (1997), vol. 100, pages 2254 - 2262 | - YING ET AL., J. IMMUNOL., (1999), vol. 99, pages 6321 - 6329 | - HUMBLES ET AL., PROC. NATL. ACAD. SCI. USA, (2002), vol. 99, pages 1479 - 1484 | - MA ET AL., J. CLIN. INVEST., (2002), vol. 109, pages 621 - 628 | - POPE ET AL., J. IMMUNOL., (2005), vol. 175, pages 5341 - 5350 | - FULKERSON ET AL., PROC. NATL. ACAD. SCI. USA, (2006), vol. 103, pages 16418 - 16423 | - HEATH ET AL., J. CLIN. INVEST., (1997), vol. 99, pages 178 - 184 | - GRIMALDI ET AL., J. LEUKOCYTE BIOL., (1999), vol. 65, pages 846 - 853 | - JUSTICE ET AL., AM. J. PHYSIOL., (2003), vol. 284, pages L168 - L178 | - TAKADA ET AL., Encyclopedia of Controlled Drug Delivery, WILEY, (1999), vol. 2 | - SANTUS, BAKER, J., CONTROLLED RELEASE, (1995), vol. 35, pages 1 - 21 | - VERMA ET AL., DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, (2000), vol. 26, pages 695 - 708 | - VERMA ET AL., J. CONTROLLED RELEASE, (2002), vol. 79, pages 7 - 27 | - LINO ET AL., "Molecular cloning and functional characterization of cynomolgus monkey (Macacafascicularis) CC chemokine receptor, CCR3", CYTOKINE, (2002), vol. 19, pages 276 - 286 | US20100764249 | US20100764894 | US20100764900 |